eFFECTOR Therapeutics Inc (NASDAQ:EFTR) backtracked Tuesday on word the health-care company entered into an investment agreement with Lincoln Park Capital for up to $50 million over 36 months.
The Company said a new group was added to evaluate frontline maintenance in patients with PD-L1 ≥1% in the Phase 2b KICKSTART trial of tomivosertib combined with Merck & Co Inc's (NYSE:MRK)
Keytruda (pembrolizumab) for non-small cell lung cancer (NSCLC).
This cohort will enroll approximately 60 patients.
Topline data from the ongoing frontline cohort in patients with PD-L1>50% and the new frontline maintenance cohort in patients with PD-L1>1% in the KICKSTART trial are now expected in H1 2023.
eFFECTOR also said it was discontinuing the development of tomivosertib in patients who have already progressed on pembrolizumab monotherapy.
In addition, first patients have been dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and combination with abemaciclib and fulvestrant in ER+/HER2- breast cancer.
eFFECTOR anticipates initial response data from one or more of the expansion cohorts, and additional data from the Phase 1 dose-escalation portion of the trial, in 1H of 2022.
It anticipates topline results from the trial in 2H of 2022.
EFTR shares opened Tuesday lower by 54 cents, or 9%, to $5.49.
